Genmab — Marts 2024
-
@US_FDA
approves #Amivantamab WITH #CHEMOTHERAPY for #1stLine treatment of advanced non-small cell #LungCancer with #EGFR #Exon20 mutations.Approval based on #Papillion trial https://twitter.com/RManochakian/status/1763620782834418055
-
"Amivantamab is a fully human bispecific antibody. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. (Janssen) to create and develop bispecific antibodies using Genmab's DuoBody
technology platform. Janssen is responsible for the development and commercialization of amivantamab". -
-
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons https://www.proinvestor.com/investornyt/1126030/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons
-
JNJ: RYBREVANT
(amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations -
JNJ har udtalt at de går efter hele egfr markedet ved at tage markedsandele fra Tigresso (AstaZenaca), der omsætter for ca $6 bn årligt. De første data vi så for nylig i JNJs kombi forsøg, hvor Rybrevant var det ene stof, var ikke helt overbevisende/understøttende for at kunne nå det mål. Tigresso er ikke godkendt i exon 20 mutationen.
-
Et lidt andet perspektiv på den påståede grådighed findes på side 109-111 i årsrapporten. Samlet set koster løn, bonus, resticted stocks mv til bestyrelsen og Excecutive management (8 personer) i 2023 i alt 174 mio dkk eller svarende til under 3 kr pr aktie vi ejer https://ir.genmab.com/static-files/85c13ec9-cebd-4a45-9be1-ecf50a112ca8
-
Hvor har du det snit fra. Det er vel tallene side 110, der er gældende for bestyrelsen? Det er vel nærmere 1.2 Mio. DKK i snit?
-
Jeg klan meget vel tage fejl
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind